Cargando…
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs), has shown promising clinical outcomes in many cancers; however, these therapies have significant limitations, such as poor pharmacokinetics and the ability to target only one antigen on the cancer cells. In multi...
Autores principales: | Alhallak, Kinan, Sun, Jennifer, Wasden, Katherine, Guenthner, Nicole, O’Neal, Julie, Muz, Barbara, King, Justin, Kohnen, Daniel, Vij, Ravi, Achilefu, Samuel, DiPersio, John F., Azab, Abdel Kareem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292428/ https://www.ncbi.nlm.nih.gov/pubmed/33479469 http://dx.doi.org/10.1038/s41375-021-01127-2 |
Ejemplares similares
-
Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022) -
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020) -
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia
por: Alhallak, Kinan, et al.
Publicado: (2021) -
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
por: Federico, Cinzia, et al.
Publicado: (2020) -
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
por: Alhallak, Kinan, et al.
Publicado: (2021)